The effects of single nucleotide polymorphisms in CYP2A13 on metabolism of 5-methoxypsoralen

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2110-2116

  Goto, Tatsushi ^a   Moriuchi, Hiroshi ^a   Fu, Xuejun ^a   Ikegawa, Tomoyo ^a   Matsubara, Toshiyuki ^b   Chang, Gang ^c   Uno, Tomohide ^a   Morigaki, Kenichi ^a,c   Isshiki, Kunio ^b   Imaishi, Hiromasa ^a  

^a KOBE UNIVERSITY   (Japan)

^b MERCIAN CORPORATION   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYPSORALEN DIHYDRODIOL; BERGAPTEN; CYTOCHROME P450 2A; CYTOCHROME P450 2A13; DNA; DRUG METABOLITE; PROTEIN; RECOMBINANT ENZYME; UMBELLIFERONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG METABOLISM; ESCHERICHIA COLI; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; ESCHERICHIA COLI; HUMANS; METHOXSALEN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 78649559836     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034553     Document Type: Article

References (34)

1. Bao Z, He XY, Ding X, Prabhu S, and Hong JY (2005) Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 33:258-261.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Fukami T, Nakajima M, Sakai H, Katoh M, and Yokoi T (2007) CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos 35:335-339.
4. Gu J, Su T, Chen Y, Zhang QY, and Ding X (2000) Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 165:158-162.
5. He XY, Shen J, Ding X, Lu AY, and Hong JY (2004) Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Drug Metab Dispos 32:1516-1521. (Pubitemid 39564574)
6. He XY, Tang L, Wang SL, Cai QS, Wang JS, and Hong JY (2006) Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer 118:2665-2671.
7. Imaishi H, Matsuo S, Swai E, and Ohkawa H (2000) CYP78A1 preferentially expressed in developing inflorescences of Zea mays encoded a cytochrome P450-dependent lauric acid 12-monooxygenase. Biosci Biotechnol Biochem 64:1696-1701.
8. Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, and Kamataki T (1998) High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315-1325.
9. Jalas JR, Ding X, and Murphy SE (2003) Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab Dispos 31:1199-1202.
10. Jeurissen SM, Bogaards JJ, Awad HM, Boersma MG, Brand W, Fiamegos YC, van Beek TA, Alink GM, Sudhölter EJ, Cnubben NH, et al. (2004) Human cytochrome p450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1′-hydroxysafrole. Chem Res Toxicol 17:1245-1250.
11. Jeurissen SM, Bogaards JJ, Boersma MG, ter Horst JP, Awad HM, Fiamegos YC, van Beek TA, Alink GM, Sudhölter EJ, Cnubben NH, et al. (2006) Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol. Chem Res Toxicol 19:111-116.
12. Jeurissen SM, Punt A, Boersma MG, Bogaards JJ, Fiamegos YC, Schilter B, van Bladeren PJ, Cnubben NH, and Rietjens IM (2007) Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem Res Toxicol 20:798-806.
13. John BA, Chasseaud LF, Wood SG, and Forlot P (1992) Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog. Xenobiotica 22:1339-1351.
14. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
15. Koenigs LL and Trager WF (1998) Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37:10047-10061.
16. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, Anttila S, Fernandez-Salguero P, Gonzalez F, and Raunio H (1999) Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 57:1407-1413.
17. McNeely W and Goa KL (1998) 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 56:667-690.
18. Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, and Yokoi T (2006) CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 119:2520-2526.
19. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
20. Reilly CA and Yost GS (2006) Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev 38:685-706.
21. Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, and Tyndale RF (2003) The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone (NNK) metabolism in vivo. Nicotine Tob Res 5:891-899. (Pubitemid 38029085)
22. Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, and Scott EE (2007) Structure of the human lung cytochrome P450 2A13. J Biol Chem 282:17306-17313.
23. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079.
24. Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Hönigsmann H, and Tanew A (2010) 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 162:655-660.
25. von Weymarn LB and Murphy SE (2003) CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6. Xenobiotica 33:73-81.
26. von Weymarn LB, Zhang QY, Ding X, and Hollenberg PF (2005) Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 26:621-629. (Pubitemid 41214152)
27. Wackernagel A, Hofer A, Legat F, Kerl H, and Wolf P (2006) Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br J Dermatol 154:519-523.
28. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, and Lin D (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63:8057-8061.
29. Wang SL, He XY, Shen J, Wang JS, and Hong JY (2006) The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant. Toxicol Sci 94:38-45.
30. Yun CH, Yim SK, Kim DH, and Ahn T (2006) Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab 7:411-429.
31. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423.
32. Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, and Ding X (2007) CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. J Pharmacol Exp Ther 323:570-578.
33. Zhou SF, Xue CC, Yu XQ, and Wang G (2007) Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 8:526-553.
34. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, Wang SL, Yang CS, He XY, and Hong JY (2006) CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 34:1672-1676.